Amantadine as an Alternative to VMAT2 Inhibitors for Tardive Dyskinesia in Patients at Risk of Depression and Suicidality

Journal of Clinical Psychopharmacology · Published 2026-04-03 · DOI 10.1097/jcp.0000000000002169

Authors being retrieved — see the publisher record. https://doi.org/10.1097/jcp.0000000000002169

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Progress on Pharmacogenetic Tests for Antidepressant Drug Selection Requires Properly Designed Studies · Journal of Clinical Psychopharmacology · 2026 · Same journal
• Journal of Clinical Psychopharmacology Updates · Journal of Clinical Psychopharmacology · 2026 · Same journal
• Vortioxetine Related Hypertriglyceridemia in a Young Male · Journal of Clinical Psychopharmacology · 2026 · Same journal
• Sugarless Candy in Treatment-Resistant Clozapine-Induced Sialorrhea · Journal of Clinical Psychopharmacology · 2026 · Same journal
• Safety of Adjunct Low-Dose Methylphenidate Extended-Release for Cognitive Deficits in Stable Schizophrenia · Journal of Clinical Psychopharmacology · 2026 · Same journal
• Menorrhagia Associated With Extended-Release Methylphenidate in an Adult Woman · Journal of Clinical Psychopharmacology · 2026 · Same journal
• Hypnopompic Hallucinations · Journal of Clinical Psychopharmacology · 2026 · Same journal
• Reading the Signal: What Psychedelic Trials in Depression Still Can’t Tell Us · Journal of Clinical Psychopharmacology · 2026 · Same journal
• Escitalopram-Associated Myopericarditis in a Young Adult · Journal of Clinical Psychopharmacology · 2026 · Same journal
• Are the 8 Finnish Deaths Explained by Agranulocytosis More Important than the Thousands of Suicide Deaths Associated with the Lack of Use of Clozapine? Reflections on Clozaphobia · Journal of Clinical Psychopharmacology · 2026 · Same journal